Machine Learning-Assisted Ensemble Analysis for the Prediction of Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer

被引:2
作者
Huang, Yibao [1 ]
Zhu, Qingqing [1 ]
Xue, Liru [1 ]
Zhu, Xiaoran [1 ]
Chen, Yingying [1 ]
Wu, Mingfu [1 ]
机构
[1] Huazhong Univ Sci & Technol, Natl Clin Res Ctr Obstetr & Gynecol Dis, Key Lab Canc Invas & Metastasis, Tongji Hosp,Tongji Med Coll,Dept Gynecol,Minist E, Wuhan, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
locally advanced cervical cancer; neoadjuvant chemotherapy; machine learning analysis; predictive model; pathology response; INFLAMMATION MARKERS; RADICAL HYSTERECTOMY; CURATIVE RESECTION; SURGERY; VALIDATION; FIBRINOGEN; EFFICACY;
D O I
10.3389/fonc.2022.817250
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The clinical benefit of neoadjuvant chemotherapy (NACT) before concurrent chemoradiotherapy (CCRT) vs. adjuvant chemotherapy after CCRT is debated. Non-response to platinum-based NACT is a major contributor to poor prognosis, but there is currently no reliable method for predicting the response to NACT (rNACT) in patients with locally advanced cervical cancer (LACC). In this study we developed a machine learning (ML)-assisted model to accurately predict rNACT. We retrospectively analyzed data on 636 patients diagnosed with stage IB2 to IIA2 cervical cancer at our hospital between January 1, 2010 and December 1, 2020. Five ML-assisted models were developed from candidate clinical features using 2-step estimation methods. Receiver operating characteristic curve (ROC), clinical impact curve, and decision curve analyses were performed to evaluate the robustness and clinical applicability of each model. A total of 30 candidate variables were ultimately included in the rNACT prediction model. The areas under the ROC curve of models constructed using the random forest classifier (RFC), support vector machine, eXtreme gradient boosting, artificial neural network, and decision tree ranged from 0.682 to 0.847. The RFC model had the highest predictive accuracy, which was achieved by incorporating inflammatory factors such as platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, neutrophil-to-albumin ratio, and lymphocyte-to-monocyte ratio. These results demonstrate that the ML-based prediction model developed using the RFC can be used to identify LACC patients who are likely to respond to rNACT, which can guide treatment selection and improve clinical outcomes.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Successful neoadjuvant chemotherapy plus sintilimab for locally advanced cervical cancer: case series and review of the literature
    Liu, Linlin
    Deng, Xianbo
    Guo, Shuang
    Yang, Shouhua
    DIAGNOSTIC PATHOLOGY, 2023, 18 (01)
  • [32] Neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer
    Venkataramana, Vinay Babu
    Anand, Vivek
    Bajpai, Ranjeet
    Paul, Simon
    Hinduja, Ritika
    Bhadane, Manish
    Deshpande, Sudesh
    Naidu, Suresh
    Kapadia, Asha
    Almel, Sachin
    Lala, Murad
    Venkatesan, Kannan
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S1064 - S1065
  • [33] Neoadjuvant chemotherapy: An alternative option of treatment for locally advanced cervical cancer
    Loizzi, V.
    Cormio, G.
    Vicino, M.
    Selvaggi, L.
    GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 2008, 65 (02) : 96 - 103
  • [34] Neoadjuvant Chemotherapy With the Angiogenesis Inhibitor Bevacizumab for Locally Advanced Cervical Cancer
    Baek, Sunhwa
    Noh, Ka-Won
    Zhao, Yue
    Schoemig-Markiefka, Birgid
    Ratiu, Dominik
    Domroese, Christian
    Mallmann, Michael
    Mallmann, Peter
    Pilch, Henryk
    IN VIVO, 2024, 38 (06): : 3068 - 3077
  • [35] A prospective phase II study of topotecan (Hycamtin®) and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer
    Manci, N.
    Marchetti, C.
    Di Tucci, C.
    Giorgini, M.
    Esposito, F.
    Palaia, I.
    Musella, A.
    Perniola, G.
    Carrone, A.
    Panici, P. Benedetti
    GYNECOLOGIC ONCOLOGY, 2011, 122 (02) : 285 - 290
  • [36] Feasibility and safety of carboplatin plus paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: a pilot study
    Angioli, Roberto
    Plotti, Francesco
    Luvero, Daniela
    Aloisi, Alessia
    Guzzo, Federica
    Capriglione, Stella
    Terranova, Corrado
    Nardone, Carlo De Cicco
    Benedetti-Panici, Pierluigi
    TUMOR BIOLOGY, 2014, 35 (03) : 2741 - 2746
  • [37] The Diversity of Vaginal Microbiota Predicts Neoadjuvant Chemotherapy Responsiveness in Locally Advanced Cervical Cancer
    Zizhuo Wang
    Rourou Xiao
    Jia Huang
    Xu Qin
    Dianxing Hu
    Ensong Guo
    Chen Liu
    Funian Lu
    Lixin You
    Chaoyang Sun
    Gang Chen
    Microbial Ecology, 2022, 84 : 302 - 313
  • [38] The Value of Diffusion-Weighted Magnetic Resonance Imaging in Assessing the Response of Locally Advanced Cervical Cancer to Neoadjuvant Chemotherapy
    Fu, Chun
    Bian, Dujun
    Liu, Fengying
    Feng, Xiaoyan
    Du, Wanping
    Wang, Xiangquan
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2012, 22 (06) : 1037 - 1043
  • [39] Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation Versus Adjuvant Chemotherapy Following Concurrent Chemoradiation for Locally Advanced Cervical Cancer: A Network Meta-Analysis
    Suh, Young Ju
    Lee, Dae Hyung
    Lee, Hee Joong
    Lee, Banghyun
    CANCERS, 2025, 17 (02)
  • [40] PRMT1 expression predicts response to neoadjuvant chemotherapy for locally advanced uterine cervical cancer
    Shimomura, Masahiro
    Fukuda, Takeshi
    Awazu, Yuichiro
    Nanno, Shigenori
    Inoue, Yuta
    Matsubara, Hiroaki
    Yamauchi, Makoto
    Yasui, Tomoyo
    Sumi, Toshiyuki
    ONCOLOGY LETTERS, 2021, 21 (02)